Simplify Health Care ETF

PINK
$38.89 -0.05 (-0.13%)
Dividend Yield 0.64%
Payout Frequency Quarterly

Dividend History

Pay DateAmountEx-DateRecord Date
June 30, 2026$0.052026-06-252026-06-25
March 31, 2026$0.052026-03-262026-03-26
December 31, 2025$0.102025-12-232025-12-23
September 30, 2025$0.052025-09-252025-09-25
June 30, 2025$0.052025-06-252025-06-25

Dividends Summary

Company News

iShares U.S. Pharmaceuticals ETF Tops Simplify Health Care ETF Returns
The Motley Fool • Brendan Coffey • June 10, 2026

The iShares U.S. Pharmaceuticals ETF (IHE) outperformed the Simplify Health Care ETF (PINK) over the past year, delivering 42.40% returns versus 29.30%. IHE offers lower costs (0.38% expense ratio), higher dividend yield (1.62%), and focuses on established pharmaceutical giants like Eli Lilly and Johnson & Johnson. While PINK provides active mana...

Billionaire Investor Takes New Stake In Thermo Fisher Scientific
Benzinga • Lekha Gupta • April 30, 2026

Hedge fund billionaire Daniel Loeb's Third Point LLC acquired a stake in Thermo Fisher Scientific (TMO) in Q4 2025, purchasing 50,000 shares. The company reported strong Q1 2026 earnings of $5.44 per share, beating expectations, with 6% YoY revenue growth to $11.01 billion. TMO raised full-year guidance for both earnings and sales. However, the s...

'Own what the Mother of All Bubbles crowd doesn't': This market strategist expects stagflation and is investing for it now.
MarketWatch • MarketWatch • August 26, 2023

"The bond market is saying the Fed is going to remain tight and seriously consider another rate hike in September," strategist Keith McCullough says.

'The Fed is way late and they’ve already screwed it up.' This stock strategist is banking on gold, silver and Treasurys to weather a recession.
MarketWatch • MarketWatch • May 13, 2023

Hedgeye's Keith McCullough says the market is in denial: 'Investors just want their bubble back.'

ETFs in Focus on Sanofi and Regeneron's COPD Drug Data
Zacks Investment Research • Sanghamitra Saha • March 24, 2023

Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.

Related Companies